InvestorsHub Logo
Followers 2
Posts 254
Boards Moderated 0
Alias Born 08/02/2017

Re: None

Friday, 03/09/2018 9:38:50 AM

Friday, March 09, 2018 9:38:50 AM

Post# of 421
News! "RBC Capital initiates coverage on Proteostasis Therapeutics (NASDAQ: PTI) with a Outperform rating and a price target of $11.00. Analyst Brian Abrahams said the company's CF assets has some promising preclinical signals and early clinical promise."